Form 4: IGMS Acquired: Topsoe Holding Exits Stake

Topsoe Holding A/S reports the disposition of its entire stake in IGM Biosciences, Inc. following the company's merger into a wholly-owned subsidiary of Concentra Biosciences, LLC.

Summary

• Topsoe Holding A/S, previously a 10% owner and director of IGM Biosciences, Inc. (IGMS), has reported the complete disposition of its beneficial ownership in IGMS.
• This disposition occurred on August 14, 2025, as a direct result of the merger of IGM Biosciences, Inc. with Concentra Merger Sub V, Inc., a wholly-owned subsidiary of Concentra Biosciences, LLC.
• In connection with the merger, each outstanding share of IGM Biosciences' Common Stock and Non-Voting Common Stock was cancelled.
• Former shareholders received $1.247 in cash and one contractual contingent value right (CVR) for each share.
• Topsoe Holding A/S disposed of 10,400,564 shares of Common Stock and 5,044,295 shares of Non-Voting Common Stock.
• Prior to the merger, the Non-Voting Common Stock was convertible into Common Stock on a 1-for-1 basis, subject to a 4.99% beneficial ownership limitation.

Sentiment

Score: 7

Explanation: The filing reports the expected completion of a merger, which provides a clear exit and monetization for the reporting entity's investment. While the CVR introduces some uncertainty, the overall event is a planned strategic outcome, indicating a positive resolution for the reporting shareholder's stake.

Positives

• Topsoe Holding A/S successfully monetized its investment in IGM Biosciences through the merger, receiving a combination of cash and Contingent Value Rights (CVRs).
• The merger provides a clear and complete exit strategy for Topsoe Holding A/S from its significant equity stake in IGM Biosciences.

Negatives

• Topsoe Holding A/S no longer holds an equity stake in IGM Biosciences, indicating a complete divestment from the company.
• The ultimate value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events, introducing a speculative component to the merger consideration.

Risks

• The value of the Contingent Value Right (CVR) is subject to the achievement of specific future performance or milestones, which may not be met, potentially limiting the total return for former shareholders.
• Topsoe Holding A/S no longer has direct exposure to the future growth or decline of IGM Biosciences as an independent, publicly traded entity.

Future Outlook

IGM Biosciences, Inc. has transitioned into a wholly-owned subsidiary of Concentra Biosciences, LLC, meaning its future operations and strategic direction will now be determined by its new parent company. The Contingent Value Rights (CVRs) represent a potential future payout tied to specific contingent events or milestones.

Management Comments

• Jakob Haldor Topsoe, Christina Teng Topsoe, Anne Haugwitz-Hardenberg-Reventlow, Emil Oigaard, Thomas Schleicher and Birgitte Nielsen, members of the board of directors of Topsoe Holding A/S, may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein, if any.

Industry Context

This merger represents a consolidation event within the biotechnology or pharmaceutical sector, a common trend where larger entities acquire smaller, often clinical-stage, companies. Such transactions allow acquirers to integrate promising pipelines or technologies, while providing an exit and value realization for the acquired company's shareholders, frequently incorporating contingent components like CVRs to bridge valuation gaps related to future milestones.

Comparison to Industry Standards

• The inclusion of a Contingent Value Right (CVR) as part of the merger consideration is a standard practice in biotech and pharmaceutical acquisitions, particularly when the acquired company's value is heavily reliant on future clinical or regulatory achievements. This structure allows the acquirer to manage upfront costs while offering potential upside to selling shareholders if specific targets are met.
• Similar CVR structures have been observed in notable industry acquisitions, such as Sanofi's acquisition of Principia Biopharma and Bristol Myers Squibb's acquisition of MyoKardia, where payouts were contingent on drug approvals or sales milestones.
• The combination of a cash component ($1.247 per share) and a CVR aligns with typical deal structures for life sciences companies at various stages of development, reflecting both immediate liquidity and potential future value.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (former): Received $1.247 cash per share and one CVR, converting their equity into a combination of immediate cash and a contingent future payment.
• Employees: While not explicitly detailed, mergers often lead to integration efforts that can impact employee roles, compensation, and corporate culture.
• Creditors: The change in ownership structure may affect the credit profile or covenants, though specific details are not provided in this filing.

Next Steps

• The value realization of the Contingent Value Rights (CVRs) will depend on the achievement of specific milestones or conditions outlined in the CVR Agreement.

Key Dates

Recommendation

For former shareholders of IGM Biosciences, Inc., the merger has completed, and their shares have been converted into cash and Contingent Value Rights (CVRs). There is no longer an equity stake in IGM Biosciences to buy or sell on the public market. The recommendation to 'hold' applies to the CVRs, as their value is contingent on future events and should be monitored by the holders.

Keywords

IGM Biosciences, IGMS, Topsoe Holding A/S, Merger, Acquisition, Form 4, SEC Filing, Beneficial Ownership, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals